1: Zhou H, Rao J, Lin J, Yin B, Sheng H, Lin F, Zhang N, Yang L. The insulin- like growth factor-I receptor kinase inhibitor NVP-ADW742 sensitizes medulloblastoma to the effects of chemotherapy. Oncol Rep. 2011 Jun;25(6):1565-71. doi: 10.3892/or.2011.1233. Epub 2011 Mar 23. PMID: 21455580.
2: Martins AS, Mackintosh C, Martín DH, Campos M, Hernández T, Ordóñez JL, de Alava E. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40. doi: 10.1158/1078-0432.CCR-05-1778. PMID: 16740780.
3: Warshamana-Greene GS, Litz J, Buchdunger E, García-Echeverría C, Hofmann F, Krystal GW. The insulin-like growth factor-I receptor kinase inhibitor, NVP- ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res. 2005 Feb 15;11(4):1563-71. doi: 10.1158/1078-0432.CCR-04-1544. PMID: 15746061.
4: He Y, Zhang J, Zheng J, Du W, Xiao H, Liu W, Li X, Chen X, Yang L, Huang S. The insulin-like growth factor-1 receptor kinase inhibitor, NVP-ADW742, suppresses survival and resistance to chemotherapy in acute myeloid leukemia cells. Oncol Res. 2010;19(1):35-43. doi: 10.3727/096504010x12828372551821. PMID: 21141739.
5: Warshamana-Greene GS, Litz J, Buchdunger E, Hofmann F, García-Echeverría C, Krystal GW. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol Cancer Ther. 2004 May;3(5):527-35. PMID: 15141010.
6: Zong R, Chen X, Feng J, Xu S. IGF-1R depletion sensitizes colon cancer cell lines to radiotherapy. Cancer Biomark. 2021;32(2):199-206. doi: 10.3233/CBM-210016. PMID: 34092618.
7: Alfaro-Arnedo E, López IP, Piñeiro-Hermida S, Ucero ÁC, González-Barcala FJ, Salgado FJ, Pichel JG. IGF1R as a Potential Pharmacological Target in Allergic Asthma. Biomedicines. 2021 Jul 29;9(8):912. doi: 10.3390/biomedicines9080912. Erratum in: Biomedicines. 2022 Mar 22;10(4): PMID: 34440118; PMCID: PMC8389607.
8: Yamagishi A, Ikeda Y, Ikeuchi M, Yuki R, Saito Y, Nakayama Y. Targeting Insulin-Like Growth Factor 1 Receptor Delays M-Phase Progression and Synergizes with Aurora B Inhibition to Suppress Cell Proliferation. Int J Mol Sci. 2020 Feb 5;21(3):1058. doi: 10.3390/ijms21031058. PMID: 32033461; PMCID: PMC7037296.
9: Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, García-Echeverría C, Pearson MA, Hofmann F, Anderson KC, Kung AL. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004 Mar;5(3):221-30. doi: 10.1016/s1535-6108(04)00050-9. PMID: 15050914.
10: Chablais F, Jazwinska A. IGF signaling between blastema and wound epidermis is required for fin regeneration. Development. 2010 Mar;137(6):871-9. doi: 10.1242/dev.043885. PMID: 20179093.
11: Lahne M, Piekos SM, O'Neill J, Ackerman KM, Hyde DR. Photo-regulation of rod precursor cell proliferation. Exp Eye Res. 2019 Jan;178:148-159. doi: 10.1016/j.exer.2018.09.015. Epub 2018 Sep 27. PMID: 30267656.
12: Morgan GJ, Krishnan B, Jenner M, Davies FE. Advances in oral therapy for multiple myeloma. Lancet Oncol. 2006 Apr;7(4):316-25. doi: 10.1016/S1470-2045(06)70657-X. PMID: 16574547.
13: Agulló-Ortuño MT, Díaz-García CV, Agudo-López A, Pérez C, Cortijo A, Paz- Ares L, López-Ríos F, Pozo F, de Castro J, Cortés-Funes H, López Martín JA. Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer. J Cancer Res Clin Oncol. 2015 Jan;141(1):43-53. doi: 10.1007/s00432-014-1787-z. Epub 2014 Aug 1. PMID: 25081930.
14: Thamm DH, Huelsmeyer MK, Mitzey AM, Qurollo B, Rose BJ, Kurzman ID. RT-PCR- based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target. Melanoma Res. 2010 Feb;20(1):35-42. doi: 10.1097/CMR.0b013e328331ca86. PMID: 19949352.
15: Chen L, Zhu Z, Gao W, Jiang Q, Yu J, Fu C. Systemic analysis of different colorectal cancer cell lines and TCGA datasets identified IGF-1R/EGFR-PPAR- CASPASE axis as important indicator for radiotherapy sensitivity. Gene. 2017 Sep 5;627:484-490. doi: 10.1016/j.gene.2017.07.003. Epub 2017 Jul 4. PMID: 28687332.
16: Xie L, Tang Q, Yang L, Chen L. Insulin-like growth factor I promotes oocyte maturation through increasing the expression and phosphorylation of epidermal growth factor receptor in the zebrafish ovary. Mol Cell Endocrinol. 2016 Jan 5;419:198-207. doi: 10.1016/j.mce.2015.10.018. Epub 2015 Oct 24. PMID: 26599586.
17: Hewish M, Chau I, Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov. 2009 Jan;4(1):54-72. doi: 10.2174/157489209787002515. PMID: 19149688.
18: Ozkan EE. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Mol Cell Endocrinol. 2011 Sep 15;344(1-2):1-24. doi: 10.1016/j.mce.2011.07.002. Epub 2011 Jul 18. PMID: 21782884.
19: Catalano R, Giardino E, Treppiedi D, Mangili F, Morelli V, Elli FM, Serban AL, Luconi M, Mannelli M, Spada A, Arosio M, Mantovani G, Peverelli E. The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells. Cancer Lett. 2021 Jan 28;497:77-88. doi: 10.1016/j.canlet.2020.10.022. Epub 2020 Oct 16. PMID: 33075426.
20: Dent P, Han SI, Mitchell C, Studer E, Yacoub A, Grandis J, Grant S, Krystal GW, Hylemon PB. Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes. Biochem Pharmacol. 2005 Nov 25;70(11):1685-96. doi: 10.1016/j.bcp.2005.08.020. Epub 2005 Oct 3. PMID: 16207485.